Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01300468 · ClinicalTrials.gov registry record · Phase 1
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors
A Phase 1 study, sponsored by Nerviano Medical Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01300468 is a Phase 1 study that has completed, run by Nerviano Medical Sciences. The registered enrollment target is 38 participants.
The verdict
NCT01300468, a Phase 1 study, has completed, sponsored by Nerviano Medical Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid tumor patients. Objectives of the study were to determine the maximum tolerated dose and the dose that can be recommended for Phase II investigations.
Interventions
- DRUG PHA-848125AC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01300468
The ClinicalTrials.gov registry entry for NCT01300468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nerviano Medical Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PHA-848125AC is the first listed.
NCT01300468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01300468 about?
NCT01300468 is a clinical study titled "Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors". The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid tumor patients. Objectives of the study were to determine the maximum to...
What is the current status of trial NCT01300468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2006-04. Estimated completion is 2009-12.
What interventions are being tested in trial NCT01300468?
The interventions under investigation include: PHA-848125AC (DRUG).
Who is sponsoring clinical trial NCT01300468?
This trial is sponsored by Nerviano Medical Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.